In October 2018, Coherent Biopharma completed its Series A2 fundraising of 20 million USD led by 6 Dimensions Capital to facilitat...
On August 1, 2018, CBP-1008 for injection, a Class I new drug independently developed by Coherent Biopharma, was approved by SFDA...